Active Ingredient History
Buprenorphine is an opioid analgesic, used to treat opioid addiction, moderate acute pain, and moderate chronic pain. Buprenorphine is a partial agonist at the mµ-opioid receptor and an antagonist at the kappa-opioid receptor. One unusual property of buprenorphine observed in vitro studies is its very slow rate of dissociation from its receptor. This could account for its longer duration of action than morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. The principal action of the therapeutic value of buprenorphine is analgesia and is thought to be due to buprenorphine binding with high affinity to opioid receptors on neurons in the brain and spinal cord. Buprenorphine produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation. Buprenorphine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Buprenorphine produces peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 4)
Acute Pain (Phase 4)
Adjuvants, Anesthesia (Phase 4)
Alcoholism (Phase 3)
Analgesics (Phase 4)
Analgesics, Opioid (Phase 4)
Anemia, Sickle Cell (Phase 2)
Anesthesia and Analgesia (Early Phase 1)
Anesthesia, Local (Phase 4)
Antiretroviral Therapy, Highly Active (Phase 2)
Anxiety (Phase 2/Phase 3)
Anxiety Disorders (Phase 4)
Arthralgia (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Arthroplasty (Phase 4)
Arthroplasty, Replacement, Hip (Phase 4)
Arthroplasty, Replacement, Knee (Early Phase 1)
Back Pain (Phase 3)
Behavior, Addictive (Phase 1)
Buprenorphine (Phase 4)
Cancer Pain (Phase 4)
Chronic Pain (Phase 4)
Cocaine-Related Disorders (Phase 3)
Cognition Disorders (Phase 4)
Dementia (Phase 4)
Dental Caries (Phase 4)
Depression (Phase 4)
Depressive Disorder (Phase 3)
Depressive Disorder, Major (Phase 4)
Diagnosis, Dual (Psychiatry) (Phase 4)
Dilatation (Phase 4)
Drug Misuse (Phase 2)
Drug Overdose (Phase 4)
Drug-Related Side Effects and Adverse Reactions (Phase 1/Phase 2)
Drugs, Investigational (Phase 2)
Electrocardiography (Phase 1)
Estradiol (Phase 1)
General Surgery (Phase 4)
Healthy Volunteers (Phase 4)
Heart (Phase 4)
Hepacivirus (Phase 1)
Hepatitis C (Phase 4)
Hepatitis C, Chronic (Phase 4)
Heroin Dependence (Phase 4)
HIV (Phase 4)
HIV Infections (Phase 4)
Immune System Diseases (Phase 2)
Inflammation (Phase 2)
Intubation (Phase 3)
Kidney Failure, Chronic (Phase 2)
Liver Diseases (Phase 4)
Liver Failure (Phase 4)
Low Back Pain (Phase 4)
Marijuana Abuse (Phase 4)
Methadone (Phase 2)
Morphine Dependence (Phase 3)
Myalgia (Phase 4)
Myeloablative Agonists (Phase 3)
Naltrexone (Phase 2)
Neonatal Abstinence Syndrome (Phase 3)
Neonatology (Phase 1/Phase 2)
Neoplasms (Phase 4)
Neuralgia (Phase 3)
Opiate Alkaloids (Phase 4)
Opiate Overdose (Phase 4)
Opiate Substitution Treatment (Phase 3)
Opioid-Related Disorders (Phase 4)
Osteoarthritis (Phase 4)
Osteoarthritis, Knee (Phase 3)
Pain ()
Pain, Intractable (Phase 4)
Pain, Postoperative (Phase 4)
Pain, Procedural (Phase 4)
Panic Disorder (Phase 4)
Pharmacokinetics (Phase 1)
Phobia, Social (Phase 4)
Pregnancy (Phase 3)
Pregnancy Complications (Phase 3)
Psychotic Disorders (Phase 4)
Renal Colic (Phase 4)
Respiratory Insufficiency (Phase 1)
Restless Legs Syndrome (Phase 4)
Risk Reduction Behavior (Phase 4)
Rotator Cuff Injuries (Phase 2/Phase 3)
Schizophrenia (Phase 4)
Spinal Diseases (Phase 4)
Spinal Stenosis (Phase 4)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stress Disorders, Post-Traumatic (Phase 4)
Substance Abuse, Intravenous (Phase 2)
Substance Withdrawal Syndrome (Phase 4)
Suicidal Ideation (Phase 3)
Suicide (Phase 3)
Therapeutic Equivalency (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
